Oncotech's Ophtascan™, an AI mobile diagnostic tool for cancer and diabetes screening, enters the Sri Lankan market

Wednesday, October 18, 2023

Oncotech Nordic AB, a pioneering medical technology company, this technology is set to make its debut in Sri Lanka during the upcoming autumn, thanks to a new partnership with the DiaPearl Group. Ophtascan™ is a dynamic system that offers real-time detection of pre-cancerous conditions and all four stages of lung, cervical, breast, uterine, and prostate cancers. Furthermore, it can also be applied for the early detection of type 2 diabetes.

This mobile screening technology is being actively used by healthcare professionals and patients in Central Africa, where there is a high demand for diabetes and cancer screening and diagnostics. Sigma Africa clinicians are currently employing Ophtascan™ in the Central African Republic, Democratic Republic of Congo, Liberia, and Tanzania.

In addition, this AI-driven Ophtascan™ technology is slated to be introduced in Europe through Medical Express Romania. Clinicians can conveniently use their own smartphones to capture iris images of their patients and upload them to the Oncotech server. The Oncotech AI diagnostic and machine learning system then processes and swiftly sends the results back to the clinician in under a minute. The test itself is non-invasive, quick, and requires minimal equipment, making it well-suited for remote testing, away from traditional hospital settings.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit